Pharminox appoints Iain Ross as Chairman
Nottingham, UK, 8 January 2010 - Pharminox Limited, ("Pharminox" or "the Company") the UK-based cancer drug discovery and development company, today announced that it has appointed Iain Ross as Non-executive Chairman. Mr Ross takes over from Dr Mario Polywka, who is stepping down as Chairman due to other commitments, but will remain on the Baord in a non-executive capacity.
Mr Ross is currently Non-executive Chairman of Silence Therapeutics plc, the UK-quoted biotechnology company (AIM:SLN) which recently merged with the US company Intradigm Corporation. He also holds non-executive directorships with a number of other companies in the sector.
Commenting on today's announcement, Peter Worrall, Chief Executive of Pharminox said, "The appointment of Iain Ross is an important milestone in the strategic development of Pharminox. Iain brings a wealth of experience and an impressive track record of fund raising and shareholder value generation in the biotechnology sector and will greatly strengthen the Board at this important stage in the Company's development.
"I would also like to take this opportunity to thank Mario Polywka for the tremendous contribution he has made as Chairman of the Board over the last five years. I am very pleased that Mario has agreed to remain on the Board as a non-executive director."
Iain Ross commented, "I am delighted to be joining the board of Pharminox. The Company is at an exciting stage and I have been very impressed both by the calibre of the people and the quality of the science. I look forward to working with the Board and Management Team to create real and sustainable shareholder value."